679 related articles for article (PubMed ID: 26062742)
1. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
[TBL] [Abstract][Full Text] [Related]
2. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology.
Xu C; Lo A; Yammanuru A; Tallarico AS; Brady K; Murakami A; Barteneva N; Zhu Q; Marasco WA
PLoS One; 2010 Mar; 5(3):e9625. PubMed ID: 20224781
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
[TBL] [Abstract][Full Text] [Related]
4. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
Lawrentschuk N; Lee FT; Jones G; Rigopoulos A; Mountain A; O'Keefe G; Papenfuss AT; Bolton DM; Davis ID; Scott AM
Urol Oncol; 2011; 29(4):411-20. PubMed ID: 19523858
[TBL] [Abstract][Full Text] [Related]
5. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.
Davis ID; Liu Z; Saunders W; Lee FT; Spirkoska V; Hopkins W; Smyth FE; Chong G; Papenfuss AT; Chappell B; Poon A; Saunder TH; Hoffman EW; Old LJ; Scott AM
Cancer Immun; 2007 Aug; 7():14. PubMed ID: 17705350
[TBL] [Abstract][Full Text] [Related]
7. The novel CA IX inhibition antibody chKM4927 shows anti-tumor efficacy in vivo.
Yamaguchi A; Usami K; Shimabe M; Hasegawa K; Asada M; Motoki K; Tahara T; Masuda K
Anticancer Res; 2015 Apr; 35(4):1997-2004. PubMed ID: 25862852
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.
Birkhäuser FD; Koya RC; Neufeld C; Rampersaud EN; Lu X; Micewicz ED; Chodon T; Atefi M; Kroeger N; Chandramouli GV; Li G; Said JW; McBride WH; Kabbinavar FF; Ribas A; Pantuck AJ; Belldegrun AS; Riss J
J Immunother; 2013 Feb; 36(2):102-11. PubMed ID: 23377663
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non-renal cancer model.
Zatovicova M; Jelenska L; Hulikova A; Ditte P; Ditte Z; Csaderova L; Svastova E; Schmalix W; Boettger V; Bevan P; Pastorek J; Pastorekova S
Int J Oncol; 2014 Dec; 45(6):2455-67. PubMed ID: 25230982
[TBL] [Abstract][Full Text] [Related]
10. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
[TBL] [Abstract][Full Text] [Related]
11. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
[TBL] [Abstract][Full Text] [Related]
12. Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects.
Wang Y; Buck A; Piel B; Zerefa L; Murugan N; Coherd CD; Miklosi AG; Johal H; Bastos RN; Huang K; Ficial M; Laimon YN; Signoretti S; Zhong Z; Hoang SM; Kastrunes GM; Grimaud M; Fayed A; Yuan HC; Nguyen QD; Thai T; Ivanova EV; Paweletz CP; Wu MR; Choueiri TK; Wee JO; Freeman GJ; Barbie DA; Marasco WA
Mol Cancer; 2024 Mar; 23(1):56. PubMed ID: 38491381
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9.
Petrul HM; Schatz CA; Kopitz CC; Adnane L; McCabe TJ; Trail P; Ha S; Chang YS; Voznesensky A; Ranges G; Tamburini PP
Mol Cancer Ther; 2012 Feb; 11(2):340-9. PubMed ID: 22147747
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts.
Garousi J; Huizing FJ; Vorobyeva A; Mitran B; Andersson KG; Leitao CD; Frejd FY; Löfblom J; Bussink J; Orlova A; Heskamp S; Tolmachev V
Sci Rep; 2019 Oct; 9(1):14907. PubMed ID: 31624303
[TBL] [Abstract][Full Text] [Related]
15. LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen.
Zisman A; Pantuck AJ; Bui MH; Said JW; Caliliw RR; Rao N; Shintaku P; Berger F; Gambhir SS; Belldegrun AS
Cancer Res; 2003 Aug; 63(16):4952-9. PubMed ID: 12941820
[TBL] [Abstract][Full Text] [Related]
16. Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes.
Kerr L; Huntoon C; Donohue J; Leibson PJ; Bander NH; Ghose T; Luner SJ; Vessella R; McKean DJ
J Immunol; 1990 May; 144(10):4060-7. PubMed ID: 2139677
[TBL] [Abstract][Full Text] [Related]
17. Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN).
Mulders P; Bleumer I; Debruyne F; Oosterwijk E
Urologe A; 2004 Sep; 43 Suppl 3():S146-7. PubMed ID: 15164181
[No Abstract] [Full Text] [Related]
18. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.
Lamers CH; Willemsen R; van Elzakker P; van Steenbergen-Langeveld S; Broertjes M; Oosterwijk-Wakka J; Oosterwijk E; Sleijfer S; Debets R; Gratama JW
Blood; 2011 Jan; 117(1):72-82. PubMed ID: 20889925
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.
Zhao Z; Liao G; Li Y; Zhou S; Zou H; Fernando S
PLoS One; 2014; 9(11):e114096. PubMed ID: 25426861
[TBL] [Abstract][Full Text] [Related]
20. T cell activation upon exposure to patient-derived tumor tissue: a functional assay to select patients for adoptive T cell therapy.
Schroten C; Kraaij R; Veldhoven JL; Berrevoets CA; den Bakker MA; Ma Q; Sadelain M; Bangma CH; Willemsen RA; Debets R
J Immunol Methods; 2010 Jul; 359(1-2):11-20. PubMed ID: 20460126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
